Back to Blog
FDA510kPMAclassificationUnited Statesregulatory

FDA 510(k) vs PMA: Which Pathway Does Your Medical Device Need?

Understand the difference between FDA 510(k) clearance and PMA approval. Learn how device classification determines your regulatory pathway, timeline, and cost for the US market.

regMD TeamMarch 21, 2026

FDA 510(k) vs PMA: Which Pathway Does Your Medical Device Need?

The US market is the largest medical device market in the world — and the FDA pathway you need is determined almost entirely by your device's classification. Get this wrong and you're looking at either unnecessary expense (PMA when 510(k) would do) or a rejection that costs you years.

Here's how to figure out which pathway applies to your device.

The Three FDA Device Classes

The FDA classifies medical devices into three regulatory classes based on risk:

ClassRiskPathwayTimelineCost (approx.)
Class ILowExempt or 510(k)3–6 months$0–$22K
Class IIModerate510(k)6–12 months$22K–$500K
Class IIIHighPMA1–3 years$500K–$75M

Most devices (47%) are Class II. About 30% are Class I. Only ~10% require the full PMA pathway.

510(k): Substantial Equivalence

The 510(k) pathway requires you to demonstrate that your device is substantially equivalent to a legally marketed device (a "predicate device"). You're not proving the device is safe and effective from scratch — you're proving it's close enough to something already on the market.

What "substantially equivalent" means:

  1. Same intended use as the predicate
  2. Same technological characteristics — OR different technology but doesn't raise new safety/effectiveness questions

510(k) by the numbers:

  • FDA user fee (FY2025): Standard fee applies (small business: 50% reduction). Check FDA MDUFA fee schedule for current rates.
  • Average review time: 130 days (but preparation takes 3–6 months)
  • Clearance rate: ~85% (of decisions)
  • Total cost including testing: $30K–$500K depending on device complexity

When 510(k) works:

  • Your device has a clear predicate on the market
  • Technology is similar to existing devices
  • No novel materials or mechanisms of action
  • Class II device (or Class I with 510(k) requirement)

PMA: Premarket Approval

PMA is the FDA's most rigorous pathway. You must provide valid scientific evidence that the device is safe and effective — typically through clinical trials.

PMA by the numbers:

  • FDA user fee (FY2025): $540,783 (small business: $135,196)
  • Average review time: 180 days (after years of clinical data collection)
  • Total cost including clinical trials: $500K–$75M+
  • Approval rate: ~80% (of applications that make it to review)

When PMA is required:

  • Class III device (life-sustaining, life-supporting, or high-risk)
  • No substantially equivalent predicate exists
  • Novel technology with new safety questions
  • Examples: heart valves, implantable defibrillators, artificial pancreas systems

De Novo: The Third Path

Many people miss the De Novo pathway — designed for novel, low-to-moderate risk devices that don't have a predicate but don't warrant PMA.

  • For: Novel devices that are Class I or II risk level but have no predicate
  • Timeline: ~150 days review (plus preparation)
  • Cost: $162,235 user fee (small business: $40,559)
  • Outcome: Creates a new classification and becomes a predicate for future 510(k)s

De Novo has become increasingly popular for digital health, AI/ML devices, and novel diagnostics.

How Classification Determines Your Pathway

Is your device Class I?
  ├── Yes → Check if exempt from 510(k) (most are)
  │         ├── Exempt → Register and list. Done.
  │         └── Not exempt → File 510(k)
  │
  ├── Class II → File 510(k) with predicate
  │              └── No predicate? → Consider De Novo
  │
  └── Class III → PMA required
                  └── Low/moderate risk but no predicate? → De Novo may work

The critical question: What's your device's classification? The FDA maintains a Product Classification Database, but navigating it requires knowing your product code, which requires understanding the regulation number, which requires... you get the idea.

Common Pathway Mistakes

1. Choosing the wrong predicate. Your predicate device should match both intended use and technology. Picking a predicate with broader claims than yours seems strategic but invites additional questions.

2. Assuming Class III means PMA. Some Class III devices have been reclassified or have specific guidance allowing alternative pathways. Check the classification regulation.

3. Ignoring De Novo. If you're building something genuinely new at Class I/II risk, De Novo is often faster and cheaper than trying to force-fit a 510(k) with a weak predicate.

4. Underestimating 510(k) timelines. The 130-day FDA review clock doesn't include the months of testing, preparation, and potential additional information requests. Budget 9–18 months total.

Beyond the US: Multi-Market Strategy

Most device companies don't enter just the US market. If you're planning EU (CE marking), Singapore (HSA), or other markets simultaneously, your US classification often influences — but doesn't determine — your classification elsewhere.

For example:

  • FDA Class II ≠ EU Class IIa (different rules apply)
  • A De Novo device in the US might qualify for HSA's abridged evaluation in Singapore
  • EU MDR's software rules (Rule 11) often classify SaMD higher than FDA does

Understanding these differences early saves months of rework.

Classify Across All Markets Instantly

Not sure which FDA class — or which pathway in 15 other jurisdictions — applies to your device? regMD's free classification tool gives you instant results across the US, EU, Singapore, Japan, and 11 more markets.

Need the full picture? The $99 lifetime access includes timelines, costs, predicate analysis, and recommended market entry sequence.

This article is for informational purposes only and does not constitute regulatory advice. Always verify classifications with FDA or a qualified regulatory consultant.

All posts